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Background: To facilitate translation of evidence into clinical practice, it is critical that clear, specific, and detailed
information about interventions is provided in publications to promote replication, appropriate aggregation in
meta-analysis, and implementation. This study examined whether twenty elements of interventions deemed
essential for such translational application were reported in sufficient detail in smoking cessation trials with
pregnant women.
Methods: Searches of electronic databases using MeSH terms and keywords identified peer-reviewed English
language studies published between 2001 and 2012. Eligible studies reported a smoking cessation intervention
targeted at pregnant women and met Cochrane’s Effective Practice and Organization of Care group study design
criteria. Each intervention arm of eligible studies was assessed against the developed twenty criteria.
Results: Thirty relevant studies reported the findings of 45 intervention arms. The mode of delivery of the
intervention was reported in 100% of intervention arms. Other well-reported criteria included reporting of the
provider who delivered the intervention (96%), sample characteristics (80%), and the intervention setting (80%).
Criteria not reported adequately included care provided to women who relapse (96% not reported), details about
training given to providers (77% not reported), and the method of quit advice advised (76% not reported). No
studies reported 100% of relevant criteria.
Conclusions: Current standards of reporting of intervention content and implementation are suboptimal. The use
of smoking cessation specific checklists for reporting of trials, standard reporting using behaviour change
taxonomies, and the publication of protocols as supplements should be considered as ways of improving the
specificity of reporting.
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The importance of detailed and accurate reporting in
randomised controlled trials
Effective translation of evidence into clinical practice
should follow a logical pathway. First, evidence should
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unless otherwise stated.methodologically rigorous randomised controlled trials,
which are considered the gold standard in evaluating the
comparative effectiveness of healthcare interventions [1].
Replication of effective interventions should then occur
to provide verification of findings, allow for the extension
and generalization of results, and ensure that adoption of
findings will be effective, efficient, and improve care [2].
The findings of well-designed trials can then be combined
in meta-analysis to increase the precision of estimations of
intervention effect [3]. Clear, specific, and actionable clin-
ical practice guidelines can then be generated for to guideLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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nated through training and accreditation processes [4].
This process of evidence generation necessitates that
randomised controlled trials, on which other informa-
tion is based, provide detailed, specific, and easily inter-
pretable information.
Quality of reporting—what is the current state of the
literature?
In the early 1990’s, a number of reviews identified sys-
temic failures to fully report the methodological character-
istics of intervention studies [2,5-7]. As a result, in 1996
the Consolidated Standards of Reporting Trials (CONSORT)
guidelines were developed to ensure uniform reporting
of the methodological aspects of randomised controlled
trials, reduce bias in estimates of intervention effective-
ness, and improve internal and external validity [8]. Use
of CONSORT criteria has been shown to improve accur-
acy and quality of reporting [9-12], and is now a pre-
requisite for publication in many journals. A number of
guidelines aimed at improving the quality of reporting
of observational studies [4] and systematic reviews
[7,13,14] have since also been published and adopted
[15]. However, less attention has been paid to ensuring
detailed and specific information is provided about the
content of interventions and precisely how they are de-
livered [16]. The adequacy of description of intervention
content and implementation is not currently captured
by these tools. CONSORT guidelines ask researchers to
report the “precise details of the treatments intended
for each group, and when and where they were actually
administered”, however more specific details including
timing of treatment, content of intervention materials,
and the intervals between delivery of intervention compo-
nents that are needed to guide clinical practice are not
captured by CONSORT or other methodological quality
rating tools including those produced by Cochrane [17].
Several recent studies have examined the extent of ac-
curate and complete reporting of essential elements of
interventions across different fields of healthcare [16-20].
In one analysis by Glasziou et al. [17], only 50% of inter-
vention studies deemed important for clinical practice se-
lected for abstraction in the journal Evidence Based
Medicine were deemed replicable. This was despite stud-
ies examined being published in high-impact journals
including The New England Journal of Medicine, The
Lancet, and The British Medical Journal. Duff et al. [18]
examined reporting of therapeutic details required for
clinical application of the findings of oncology drug trials,
finding that only 11% of trials reported all aspects deemed
to be essential for replication and clinical translation.
Currow et al. [19] examined reporting of data items
deemed essential for interpretation of study generalizability
in specialist palliative care research, finding that adequatedata was reported only 28% of the time. Most recently,
Schroter et al. [16] found that 33% of drug treatments
and 73% of non-drug treatments published in the British
Medical Journal over one year were considered non-replicable.
Despite known effective interventions, many pregnant
women do not receive best-practice smoking cessation
care
Smoking is the most significant modifiable cause of ad-
verse pregnancy outcomes. Babies born to mothers who
smoke during pregnancy have 50% greater risk of peri-
natal death [21], 60% greater risk of preterm birth [21],
and weigh on average 200 g less than babies born to non-
smoking mothers [22]. Smoking cessation during preg-
nancy reduces negative pregnancy outcomes, including
miscarriage, foetal growth retardation, preterm delivery
[23], and perinatal mortality [24]. Despite evidence for the
effectiveness of smoking cessation interventions for preg-
nant women [25], the provision of best-evidence care con-
tinues to be suboptimal. A recent review [26] found that
just over half of all healthcare providers are likely to ask
pregnant women if they smoke and provide advice to quit,
while less than one-half actually assist women to quit by
providing specific intervention or referral. Failure to ap-
propriately intervene with pregnant women who smoke
could be the result of a number of factors, including
healthcare providers not being aware of or agreeing with
the evidence for effective interventions, and perceiving
that the results of trials do not apply to their patient
group or are too difficult or too expensive to implement
[26]. Another explanation may be that poor reporting of
data in clinical trials has inhibited the implementation
of best-practice care in clinical practice.
What do clinicians need to know to translate evidence
from smoking cessation clinical trials into clinical practice?
The information reported in randomised controlled trials
should be sufficient to allow readers to assess to whom
the trial result can reasonably be applied, and how to rep-
licate the intervention. Several studies have developed
checklists for assessment of study external validity and
other information deemed important in reporting of ran-
domised controlled trials [27-30]. These criteria typically
include reporting of the setting of the study; recruitment
method; participant information, treatment, or interven-
tion delivered (duration, intensity, dose, delivery format,
timing, compliance); outcome assessment; and follow-up.
Smoking cessation interventions typically incorporate sub-
stantial behavioural components that are difficult to both
describe and reproduce. To provide appropriate clinical
care, clinicians also need clear advice about: the precise
behavioural strategies that should be used, what skill
individuals providing behavioural support should have,
how intense the intervention should be, whether to use
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who do not want to quit, and those who relapse. No
studies have examined the adequacy of reporting of this
specific information for smoking cessation trials with
pregnant women.
Aims
To examine whether twenty elements of interventions and
their implementation deemed essential for replication, im-
plementation, and aggregation of studies in meta-analysis
are reported in sufficient detail in smoking cessation trials
with pregnant women. Criteria were developed based on
previously published checklists developed to assess the ex-
ternal validity and applicability of intervention trials, and
critical assessment of the information necessary to effect-




Medline, The Cochrane Library, and PsycINFO data-
bases were searched for relevant studies using MeSH
terms and subject headings (see Table 1). Searches were
limited to studies published between 2001 and 2012.
The reference lists of previous reviews of relevant litera-
ture and the reference lists of retrieved articles were also
searched to identify any additional relevant studies. The
review protocol is available from the authors.
Inclusion and exclusion criteria
Studies were include if they: evaluated a smoking cessa-
tion intervention targeted at pregnant women; had smok-
ing cessation or abstinence as an outcome measure; used
a design endorsed by the Effective Practice and Organisa-
tion of Care (EPOC) group [31] (randomised controlled
trials; controlled clinical trials; controlled before and after
studies that provided adjustment for confounders; andTable 1 Search terms
Database Search terms
Cochrane [Smoking (MeSH) OR smoking cessation (MeSH)] AND
[pregnant women (MeSH) OR prenatal care (MeSH) OR
pregnancy (MeSH) OR postpartum period (MeSH)] AND
[clinical trial (MeSH) OR intervention studies(MeSH) OR
evaluation studies (MeSH)]
Medline [Smoking (MeSH) OR Smoking cessation (MeSH)] AND
[pregnant women (MeSH) OR prenatal care (MeSH) OR
pregnancy (MeSH) OR postpartum period (MeSH)] AND
[clinical trial (MeSH) OR Intervention studies (MeSH) OR
evaluation studies (MeSH)]
PsycInfo [Tobacco smoking (subject heading) OR smoking cessation
(subject heading)] AND [prenatal care (subject heading)
OR pregnancy (subject heading) OR postnatal period
(subject heading)] AND [clinical trial (subject heading)
OR intervention (subject heading) OR evaluation (subject
heading)]interrupted time series studies were included); and were
published in an English language peer-reviewed journal.
Studies were excluded if: the intervention was targeted
at a pregnant or postpartum woman’s partner or family
member; the intervention was targeted at changing
healthcare provider behaviour only; or the intervention
examined relapse prevention only without examining
cessation or abstinence.
Study selection
The titles and abstracts of identified studies were assessed
for relevance by one reviewer and rejected on initial
screening if the reviewer could determine that the study
did not meet inclusion criteria. The remaining studies
were retained and assessed against eligibility criteria by
two reviewers (JB and AH). A backward and forward ref-
erence list search was conducted using Web of Science for
all included studies to determine whether additional de-
tails of any studies were described in other publications
reporting the same study.
Development of checklist of essential elements
A concise checklist of elements deemed essential to the
reporting of intervention content and implementation
was developed based on previously published checklists
developed to assess the external validity and applicability
of intervention trials [32-34]; and critical assessment by
the authors of the information required to effectively pro-
vide smoking cessation care from prenatal into the post-
natal period based on recommendations contained with
clinical practice guidelines. A standard data extraction
checklist was developed, then pilot tested by two authors
(JB and AH) by independently assessing five studies using
the checklist, then meeting to refine and resolve any dis-
agreements. The data extraction checklist is described in
Table 2.
Data coding
Studies meeting eligibility criteria were coded by two in-
dividuals. Discrepancies were resolved by a third. Each
study was coded as to whether the study reported the in-
formation (yes or no). As not all criteria were relevant to
all studies (for example, some studies did not use nico-
tine replacement therapy), the proportion of all relevant
elements reported for each study was then calculated. A




The initial search yielded 319 citations, and five additional
citations were identified through reference list searches
(see Figure 1). After duplicates were removed, 258 unique
articles were assessed against eligibility criteria of which,
Table 2 Essential elements for reporting of smoking cessation interventions for pregnant women
Domain Descriptor
Recipient Is the target population clearly described? Minimum criteria: age, ethnicity, stage of pregnancy at enrolment,
socioeconomic status (either income, education or employment)
Setting Is the setting in which the intervention was implemented described? E.g., Family practice, specialist obstetrics clinic,
public hospital antenatal unit, in woman’s home.
Provider Is it clear who delivered the intervention? E.g., Nurse, Doctor, Midwife, Counsellor.
Delivery Is the mode of delivery of the intervention components described? E.g., Face-to-face, telephone, mail, internet
Is the method of delivery of the intervention described? E.g., is it part of usual care or a separate program
Schedule Is the timing of the first and last contact described
Intensity and Duration Is the total number of intended contacts for the intervention described? Must be reported for each mode of contact
Is the total time period the intervention was delivered over clear? E.g., 12 week intervention
Is the frequency of contact (the time period between each contact) described? E.g., daily, fortnightly
Is the approximate duration of each contact described? E.g., 15 minute face-to-face session
Intervention fidelity Is the number of participants who received the intervention as intended reported?
Intervention materials Is the method of quit advice provided described? E.g., recommendation to quit immediately, set quit date
Are the behavioural change approaches adequately described? Needs to refer to specific techniques used in enough
detail for replication, or refer to detailed manual that is available to reader.
Are written materials (brochures, pamphlets) adequately described? Needs to be described in a level of detail that is
replicable, OR materials publically available
Was the type, strength, frequency and duration of use of NRT described?
Was the use of incentives clearly described? Needs to describe type (financial or other), amount, frequency, conditions
under which they were provided
Was social support adequately described? Needs to include type of support (support groups, quit buddy)
Clinical Pathway Is the process of care for women unwilling to quit described? E.g., are they approached again? If so, in what timeframe
and how?
Is the process of care for women who relapse described? What support is provided? How soon after relapse and how?
Skills and Qualifications Are the skills and professional qualifications of the individual delivering the intervention described?
Training Is the process of training in the intervention adequately described? Duration/format/training manual
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described 45 intervention arms. One additional publica-
tion [65] reporting the same study methodology of an in-
cluded study [49] was identified through backwards and
forwards referencing searching. This manuscript was re-
ferred to when coding the primary manuscript, however
only the primary publication reporting the cessation or
abstinence outcome is cited in the results.Description of included studies
Twenty individually randomised controlled trials [35,37,
38,41,43,45,46,48-51,56-64], six cluster randomised con-
trolled trials [40,42,52-55], and four non-randomised con-
trolled trials (which used quasi-randomisation methods)
[36,39,44,47] were identified. The majority of studies
(n = 20) were conducted in the United States [35-38,
41,43,45-47,50,51,54,56-59,61-64], with five studies con-
ducted in the United Kingdom [39,42,49,53,60], two
in the Netherlands [40,44], and one study each con-
ducted in Poland [55], Canada [48], and New Zealand
[52]. The majority of studies used behavioural counsellingapproaches. Five studies used nicotine replacement ther-
apy [44,48,51,56,63].Quality of reporting of intervention strategies
Table 3 outlines the quality of reporting of the 45 inter-
ventions arms against the twenty criteria. The mode of
delivery of the intervention was reported in 100% of inter-
vention arms. Other basic details of the study including
the person who delivered the intervention (96%), the
characteristics of the sample (80%), the setting where
the intervention was delivered (80%), and the frequency
of contact between healthcare providers and partici-
pants (73%) were well described. All eight intervention
arms (100%) that used a financial incentive intervention
described the type, amount, frequency, and conditions
under which the incentives were provided. Five of the
six intervention arms (83%) that used nicotine replace-
ment therapy adequately described the type, strength,
frequency, and duration of use.
Criteria that were not well reported included provision
of information about the process of care for women who
184 title and abstracts excluded
74 full text manuscripts reviewed
41 full text manuscripts excluded
18 non-EPOC design
11 smoking cessation not outcome 
measure
3 dissemination trials
3 focus on partner not pregnant woman
2 healthcare professional focus
2 non-English language
1 relapse prevention only
4 post-partum women only





66 duplicate citations removed
258 title and abstracts reviewed
30 full text manuscripts included 
5 additional citations identified by 
hand searches of reference lists
Figure 1 Flow chart of search strategy, study selection and assignment.
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training given to providers who delivered the interven-
tion (77% not reported). Seventy-six percent of studies
did not provide information about the specific type of
quit advice given to participants (e.g., whether to set a
quit date or stop immediately), and 70% did not describe
the behavioural counselling techniques used in sufficient
detail for replication. Only one-half of the intervention
arms provided information about the timing of the first
and last contacts between providers and participants,
and only 45% provided information about the duration
of each contact.
Table 4 summarises the proportion of intervention ele-
ments reported for each intervention arm. No interven-
tion arms reported 100% of all relevant criteria. One
intervention arm reported 94% of relevant criteria. Thirty-
six percent of intervention arms reported less than 50% of
relevant criteria. Four intervention arms reported less than
30% of relevant criteria.
Discussion
This review assessed the adequacy of reporting of ele-
ments deemed essential for replication, implementation,
aggregation in meta-analysis, and subsequent adoption
of findings into clinical practice in smoking cessation tri-
als with pregnant women. We specifically focused onreporting in intervention studies, the findings of which
are typically used in generating recommendations for
clinical practice guidelines.
Of the 45 intervention arms, none adequately reported
100% of relevant items. Only one intervention arm re-
ported more than 80% of all items. Important informa-
tion about the delivery of interventions including the
type of quit advice provided, the behavioural interven-
tion and written materials provided, the clinical pathway
of care, and the training of interventionists were the
most poorly described. Information about the intensity
and duration of intervention contacts were generally
only reported in about one-half of all intervention arms.
These factors are critical for both replication of study
findings and implementation in clinical practice. The
intensity of an intervention carries cost, resource, and
feasibility implications for use in routine clinical practice.
When such critical data are either not reported or are
vague and non-specific, little guidance is provided about
the specific components of interventions that should be
delivered as part of routine clinical care, or the policies
and resources needed to translate best evidence practice
into care. Healthcare providers and policy makers are
instead left to interpret incomplete information, and
draw their own assumptions to fill in the gaps where de-
tail is missing.
Table 3 Number and proportion of the 45 intervention arms reporting each of the 20 criteriaa
Criteria Criteria reported Criteria not reported Criteria not applicable
N (%) N (%) N
Recipient 36 (80%) 9 (20%) 0
[35b, 36, 37c, 38, 40-44, 45b, 47b, 49b,
51b, 52c, 54, 55, 56b, 57b, 58, 59, 61,
63b, 64b]
[39, 46, 48, 50, 53, 60, 62c]
Setting 36 (80%) 9 (20%) 0
[36, 37c, 39, 41-44, 45b, 47b, 49b, 50,
51b, 52c, 53-55, 56b, 57-61, 62c, 64b]
[35b, 38, 40, 46, 48, 57, 63b]
Provider delivering
intervention
43 (96%) 2 (4%) 0
[35b, 36, 37c, 38, 40-44, 45b, 46, 47b,
49b, 50, 51b, 52c, 53-55, 56b, 57b, 58-61,
62c, 63b, 64b]
[39, 48]
Mode of delivery 45 (100%) 0(0%) 0
[35, 36, 37c, 38-44, 45b, 46, 47b, 48, 49b,
50, 51b, 52c, 53-55, 56b, 57b, 58-61, 62c,
63b, 64b]
Timing of first and last
contact
22 (49%) 23 (51%) 0
[38-40, 42, 43, 45b, 47b, 51b, 53, 56b,
57b, 59, 62, 63b, 64b]
[35b, 36, 37c, 41, 44, 46, 48, 49b, 50,




31 (69%) 14 (31%) 0
[37c, 38, 40-44, 48, 49b, 50, 51b, 53, 55,
56b, 57b, 59-61, 62c, 63b, 64b]
[35b, 36, 39, 45b, 46, 47b, 52c, 54, 58]
Total time period of
intervention delivery
27 (60%) 18 (40%) 0
[35b, 37c, 38, 40-43, 45b, 48, 53, 56b,
57b, 58-62, 63b, 64b]
[36, 39, 44, 46, 47b, 49b, 50, 51b, 52c, 54,
55, 62b]
Frequency of contact 33 (73%) 12 (27%) 0
[37c, 38, 40-43, 45b, 46, 47b, 48, 49b,
51b, 53, 55, 56b, 57b, 59, 61, 62c, 63b,
64b]
[35b, 36, 39, 44, 50, 52c, 54, 58, 60]
Approximate duration
of each contact
20 (45%) 24 (55%) 1
[37b, 38, 40, 42, 44, 49b, 50, 53, 56b,
57b, 58-61, 64b]
[35b, 36, 39, 41, 43, 45b, 46, 47b, 48,
51b, 52c, 54, 55, 62c, 63b]
[37]
Intervention fidelity 28 (63%) 17 (37%) 0
[38, 39, 41-43, 46, 47b, 48, 49b, 50, 51b,
56b, 57b, 58-60, 62c, 63b, 64b]
[35b, 36, 37c, 40, 44, 45b, 52c, 53-55, 61]
Method of quitting
advised
11 (24%) 34 (76%) 0
[38-42, 52c, 59, 63b] [35b, 36, 37c, 43, 44, 45b, 46, 47b, 48,




13 (30%) 30 (70%) 2
[38, 40, 43, 44, 49b, 50, [53, 62]
54, 57b, 59, 63b] [35b, 36, 37c, 39, 41, 42, 45b, 46, 47b, 48,
51b, 52c, 55, 56b, 58, 60, 61, 62b, 64b]
Written materials 17 (52%) 16 (48%) 12
[36, 37b, 42, 43, 49b, 50, 51b, 52b, 53,
56b, 58, 60]
[39, 40, 45b, 46, 47b, 55, 57b, 59, 61,
63b, 64b]
[35b, 37, 38, 41, 44, 48, 52, 54,
62c]
NRT 5 (83%) 1 (17%) 39
[44, 48, 56, 63b] [51] [35b, 36, 37c, 38-43, 45b, 46,
47b, 49b, 50, 51, 52c, 53-56,
57b, 58-61, 62c, 64b]
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Incentives 8 (100%) 0 (0%) 37
[45b, 47b, 62b, 64b] [35b, 36, 37c, 38-44, 46, 48,
49b, 50, 51b, 52c, 53-55, 56b,
57b, 58-62, 63b]
Social support 4 (36%) 7 (64%) 34
[37b, 46, 50] [35b, 42, 44, 51, 52b] [36-41, 43, 45b, 47b, 48, 49b,
51-55, 56b, 57b, 58-61, 62c,
63b, 64b]
Process of care for
women unwilling to
quit
10 (22%) 35(78%) 0
[36, 38, 40, 42, 55, 58, 62b, 63b] [35b, 37c, 39, 41, 43, 44, 45b, 46, 47b, 48,
49b, 50, 51b, 52c, 53, 54, 56b, 57b, 59-62,
64b]
Process of care for
women who relapse
2 (4%) 43 (96%) 0
[38, 55] [35b, 36, 37c, 39-44, 45b, 46, 47b, 48,






31 (69%) 14 (31%) 0
[35b, 36, 37c, 38, 40-44, 49b, 50, 51b,
52c, 53-55, 57b, 58-61, 63b]
[39, 45b, 46, 47b, 48, 56b, 62c, 64b]
Specific training given
to providers
10 (23%) 34 (77%) 1
[38, 49b, 50, 52, 57b, 60, 64b] [35b, 36, 37b, 39-44, 45b, 46, 47b, 48,
51b, 52b, 53-55, 56b, 58, 59, 61, 62c,
63b]
[37]
aAs intervention arms were coded, rather than whole studies, some trials with multiple intervention arms appear in two of categories.
bDenotes two intervention arms of this study were coded in the same category.
cDenotes three intervention arms of this study were coded in the same category.
Percentage reflects the proportion of studies for criteria that are applicable.
Table 4 Number and proportion of intervention elements
reported for each of the 45 intervention armsa
Intervention arms
N (%)
90% – 100% of relevant criteria 1 (2%)
[38]
80% – 89% of relevant criteria 0 (0%)
70% – 79% of relevant criteria 10 (22%)
[40, 42, 43, 49b, 57b, 59, 63b]
60% – 69% of relevant criteria 9 (20%)
[37b, 41, 50, 53, 56b, 64b]
50% – 59% of relevant criteria 9 (20%)
[37, 44, 51b, 55, 58, 60-62]
40% – 49% of relevant criteria 9 (20%)
[36, 45b, 47b, 52b, 62b]
30% – 39% of relevant criteria 3 (7%)
[48, 52, 54]
20% – 29% of relevant criteria 4 (9%)
[35b, 39, 46]
aAs intervention arms were coded, rather than whole studies, some trials with
multiple intervention arms appear in two categories.
bDenotes two intervention arms of this study were coded in the
same category.
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A number of studies have made recommendations about
ways to improve reporting in scientific studies. One sug-
gested approach is the creation of checklists that dictate
the specific elements of interventions that should be re-
ported [32]. As suggested by Glasziou et al. [17], it may be
necessary to tailor such checklists to different types of
interventions. Several attempts have been made to do
this. For example, in an attempt to improve standards in
reporting of acupuncture trials, Standards for Reporting
Interventions in Controlled Trials of Acupuncture (STRICTA)
[66] have been developed as an extension to the CONSORT
criteria. The STRICTA guidelines have since been adopted
by a number of journals publishing in acupuncture re-
search. There has been a similar call for standards of
reporting to be developed for drug administration in on-
cology [18] and surgery [67] in order to ensure consistency
in the details reported.
There are clear advantages to adopting a standard of
reporting for smoking cessation trials. Smoking cessation
interventions usually incorporate behavioural strategies,
which by their nature are often multi-factorial and can
be heavily dependent on the skills and precise behav-
iours of the person delivering the intervention. If we are
to identify the most effective, successful, and appropriate
smoking cessation strategies for pregnant women, we
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components of these trials. Michie [68] and Abraham
[69] have written extensively about this issue and sug-
gested a taxonomy of behaviour change techniques may
be useful in standardising the reporting of components of
interventions. An examination of the use of such behav-
iour change techniques in published smoking cessation
trials with pregnant women was recently conducted, with
eleven techniques identified as effective [70]. However, the
authors noted that the descriptions of interventions were
not detailed enough to allow analysis of the effectiveness
of individual techniques across studies, highlighting the
critical need for improvement in reporting for advancing
the evidence base.
Strict length limitations imposed by peer-reviewed jour-
nals may also limit the reporting of intervention detail.
Electronic methods of peer-review publication allow for
supplements or appendices providing detailed information
to be published online alongside traditional journal arti-
cles [17], and could be better used by authors to make
available study protocols as a supplement to the peer
reviewed paper, or linking the publication with the pub-
lished trial registration [68]. While this recommendation
is frequently made in many papers examining quality of
reporting [71,72], it is not yet standard practice. Some
journals are however starting to require additional infor-
mation be provided. For example, the journal Addiction
requires studies reporting behavioural interventions to in-
clude very detailed descriptions of the full study protocol
or intervention manual to be published as supplementary
material to the peer-reviewed manuscript.
Strengths and limitations of this review
The findings of this review should be considered in light
of several limitations. First, the checklist of essential ele-
ments used may not capture all of the elements relevant
for clinical translation. However, this checklist was devel-
oped based on previous studies in other areas [69,73], and
could be used as a starting point to the development of a
more comprehensive smoking cessation specific checklist.
Second, it is possible that some eligible relevant articles
were not identified by our search strategy and therefore
not included in this review. Finally, we only coded the
presence or absence of reporting of key information, not
the quality or accuracy of the information presented.
Conclusion
In order to adequately translate successful smoking cessa-
tion interventions into clinical care for pregnant women,
healthcare providers need clear guidance about which in-
terventions are most effective. The current standard of
reporting of intervention content and implementation is
suboptimal, and prohibits replication, implementation, and
generation of higher levels of evidence through aggregationin meta-analysis. This ultimately limits the translation of
research findings into practice. Clear standards for report-
ing of the methodological aspects of trials have been
adopted, but there is a demonstrated need for improve-
ment in the reporting of essential aspects of interventions
and their implementation. For trials relating to pregnant
women, increased focus on accurate and specific reporting
of the type of quit advice provided, the precise behavioural
intervention and written materials provided to participants,
the training of intervention providers, and the clinical
pathway of care are all of critical importance.
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